CSIMarket
 
Vickers Vantage Corp I  (VCKA)
Other Ticker:  
 
 


Working expenditures were growing at the VCKA in the third quarter of 2022 earnings season

VCKA announced third quarter of 2022 operating deficit of $-0.657746 millions

Published 2022-11-06T21:42:10+00:00
Goran Soko / CSIMarket.com Contributer

closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons The stockholders have not assumed some changes at the business all over the July to September 30 2022 reporting season at the Vickers Vantage Corp I. However, they consider the Biotechnology & Pharmaceuticals company's operating deficit that came in at $-0.657746 millions, in the same period.

Within the recent coming cycle of the business, the stakeholders hope for additional revenue sources to arrive as soon as possible. Those investors are less concerned about the prevailing organization's current execution at the Vickers Vantage Corp I.


Since the Vickers Vantage Corp I is nevertheless expanding the revenue sources, by some means VCKA has succeeded in the cost optimization in the third quarter of 2022 earnings season to $-0.131 millions, from the $-1.444 millions, in the third quarter of 2021.


Vickers Vantage Corp I is expected to report next financial recent numbers on December 06, 2022.


    Recently Reported Results